Bone Abstracts

Objective: Zoledronic acid (Zol) has been demonstrated to be an effective therapy to treat postmenopausal osteoporosis (PMO) in Chinese women in a 12-month post-marketing observational study (ZOOM study). As an I.V. bisphosphonates, Zol are exclusively excreted via the kidneys. We present a report of the renal function and safety data of once-yearly Zol 5 mg treatment.Subjects and methods: A total of 373 PMO patients from 30 different centers in China wi...